AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06788366 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: First-line regimen according to clinical practice
Study NCT06789822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invitation to wear the smartwatch
Description: During a consultation with the psychiatrist, and after verifying the eligibility criteria, the patient will receive oral information about the study from the psychiatrist.
Study NCT06789848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ligufalimab
Description: Ligufalimab (AK117) 45 mg/kg IV over 120 minutes on Day 1 every 3 weeks
Study NCT06789848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab (AK104) 10 mg/kg IV over 60 minuets at least 30 minutes after Ligufalimab on Day 1 every 3 weeks
Study NCT05166642 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bandgrip Micro-Anchor Wound Closure
Description: This treatment group will utilize a suture closure technique for the deep dermal layers with Bandgrip being applied to the most superficial layer of the surgical incision
Study NCT05166642 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture closure
Description: This treatment gourd will utilize suture closure technique for all layers of the surgical incision.
Study NCT06278649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation and Guided Imagery
Description: Listening to a 15 minute relaxing pre-recorded script while laying down on an exercise mat
Study NCT06789458 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Professional mechanical plaque control
Description: thisThe first step in therapy is aimed at guiding behavior change by motivating the patient to undertake successful removal of supragingival dental biofilm and risk factor control and may include the following interventions:~* Interventions to improve the effectiveness of oral hygiene \[motivation, instructions (oral hygiene instructions, OHI)~* Professional mechanical plaque removal (PMPR), which includes the professional interventions aimed at removing supragingival plaque and calculus, as well as possible plaque-retentive factors that impair oral hygiene practices.~* Adjustment of faulty restoration and polishing~* The mechanical plaque control instructions for each patient include brushing and interdental cleaning techniques.
Study NCT06148272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3971297
Description: Administered SC
Study NCT06148272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT06148272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3971297 IV
Description: Administered IV
Study NCT06790134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intelligence device
Description: This AI device can provide prompts for standard sites of pancreatic scans and anatomical structures. It may also suggest the next operation methods.
Study NCT06788470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC
Description: Intratracheal administration of umbilical cord-derived mesenchymal stem cells (MSCs).
Study NCT06788275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (MIT)
Description: Patients allocated to the MIT group will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will cycle continuously between the first and second ventilatory thresholds. The duration of each exercise session will be set according to the estimated energy expenditure of the long HIIT and short HIIT groups for each training block (energy expenditure-adjusted exercise sessions). All sessions will be supervised, and patients will be asked to avoid additional exercise. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.
Study NCT06788275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (Short HIIT)
Description: Patients allocated to the Short HIIT group will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will perform from two to four 4-repetition sets of 1-min above the second ventilatory threshold. Patients will perform 1- and 3-min active recovery periods below the first ventilatory threshold between repetitions and sets, respectively. The total time spent at high intensity will range from eight to 16 min. All sessions will be supervised, and patients will be asked to avoid additional exercise training. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.
Study NCT04629729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent
Study NCT06788275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (Long HIIT)
Description: Patients allocated to the Long HIIT will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will perform from two to four 4-min high-intensity exercise bouts above the second ventilatory threshold separated by 4-min active recovery periods below the first ventilatory threshold. The total time spent at high intensity will range from eight to 16 min. All sessions will be supervised, and patients will be asked to avoid additional exercise training. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.
Study NCT05587582 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete a survey
Study NCT05113342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Descartes-25
Description: allogeneic Mesenchymal Stem Cell product.
Study NCT06534086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) guided meditation therapy
Description: Tripp application on Meta Quest 3 VR headset
Study NCT06534086 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: No VR, local anesthetic only
Study NCT06526975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamification exercise through a videogame
Description: Different exercises will be performed through a videogame.
Study NCT06788327 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: Protocol based on the best available evidence and to be used in all participants in both groups. The standard exercises protocol will consist of three postoperative rehabilitation phases: phase I (weeks 1 to 4), phase II (weeks 5 to 8) and phase III (weeks 9 to 12). Sessions will be held 2 times a week for 12 weeks. Each session will last 45 minutes and will consist of six exercises in the phase I, eight exercises in phase II, and eight exercises in phase III.
Study NCT06788327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation
Description: Protocol based on the best available evidence and to be used in all participants in both groups. The standard exercises protocol will consist of three postoperative rehabilitation phases: phase I (weeks 1 to 4), phase II (weeks 5 to 8) and phase III (weeks 9 to 12). Sessions will be held 2 times a week for 12 weeks. Each session will last 45 minutes and will consist of six exercises in the phase I, eight exercises in phase II, and eight exercises in phase III.
Study NCT06788327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Therapy
Description: Participants will perform three exercises of the standard exercises protocol with BFRT. An auto-regulated portable BFRT SmartCuffs® 3.0 Pro system with a 17-inch long and 5-inch-wide cuff (Smart Tools Plus, United States), placed on the most proximal part of the arm, will be used. Each BFRT session will begin with a maximal occlusion test to personalize the occlusion pressure to the participant. The limb occlusion pressure (LOP) will be set at 50% of the maximum occlusion pressure in the first stage and 60% in stages II and III. The participant will perform 75 repetitions per BFRT exercise divided into 4 sets (30, 15, 15, and 15 repetitions). The load intensity during the BFRT exercises will be set near to 3 out of 10 on the Borg's CR10 scale (weak), which corresponds to 30% of a 1RM effort. After each exercise, the cuff will be deflated, and the patient will rest for two minutes.
Study NCT06788340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PK-model to decide when to dose Vedolizumab and Ustekinumab
Description: the pharmacokinetic model will include information about inflammatory parameters both in blood- and fecal samples, as well as weight, sex, previous treatments and drug concentration.
Study NCT06789224 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CATUVAB
Description: inducing of aggreation of tumor cells and immune cells via trifunctional antibody and removal of aggregates
Study NCT06788158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Incobotulinum Toxin A
Description: will be administered 2 ampoules (200 IU) of Incobotulinum toxin , injectable solution presentation 100 IU ampoule with powder diluted in 1 ml of 0.9% saline solution in a single application at 4 points, in addition to a therapeutic exercise program in the teaching service to later do it at home that will be done daily for 4 months (cryotherapy for 15 minutes on the plantar fascia, active mobilizations of the ankle and foot for 5 minutes, stretching exercises for the triceps surae and plantar fascia for 20 seconds, 3 repetitions, strengthening of intrinsic muscles of the foot).
Study NCT06788158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoid
Description: Program in which 2 ml of dexamethasone will be administered in an 8 mg/2 ml ampoule diluted in 2 ml of lidocaine injectable solution in a 50 ml bottle (20 mg/ml) in a single application at 1 point, in addition to a therapeutic exercise program in the teaching service to later do it at home that will be done daily for 4 months (cryotherapy for 15 minutes on the plantar fascia, active mobilizations of the ankle and foot for 5 minutes, stretching exercises for the triceps surae and plantar fascia for 20 seconds, 3 repetitions, strengthening of intrinsic muscles of the foot).
Study NCT06790108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intelligence device
Description: This AI device can provide prompts for standard sites of pancreatic scans and anatomical structures. It may also suggest the next operation methods.
Study NCT06790108 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Artificial intelligence device
Description: This AI device can provide prompts for standard sites of pancreatic scans and anatomical structures. It may also suggest the next operation methods.
Study NCT06789081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCAR1
Description: GCAR 1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector containing a chimeric antigen receptor (CAR) that enables the specific targeting towards tumor cells expressing the cell surface protein glycoprotein non-metastatic B (GPNMB).
Study NCT06788210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiprofessional Geriatric Emergency Team applied front-door CGA to identify patients who require inpatient care and those who can safely be discharged.
Description: In comparison to the precedent studies, this project is characterised by some innovative aspects as regards to the design of intervention:~1. the participation of both a geriatrician and a nurse expert in transitional care, with the consultancy of a social worker when needed, in the management of the elderly patient within ED, adds to the project a greater operational capacity of the multidimensional assessment (CGA) of planning the best care setting for the patient.~2. The proposed CGA model is complete in the analysis of the different domains (social, clinical, functional, cognitive-affective) and achievable in this particular urgent setting.~3. The program examines, unlike other studies, much more variables that can help to define the effectiveness of the intervention.~4. The involvement in the network program of three main hospitals of the Emilia Romagna with a pool of elderly patients afferent to ED of about 20,000 elderly/year per hospital (2019 data prior of Sars Cov2 pandemic)
Study NCT05676047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation
Description: A strategy-focused intervention aimed at improving everyday cognitive function, structured to maximize treatment dose over a short time period. The shorter time period of the treatment therapy is relative to the one and only current randomized controlled trial of cognitive rehabilitation for military mTBI, the Study of Cognitive Rehabilitation Effectiveness (SCORE).
Study NCT05676047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The Education group will receive information about self-management of cognitive symptoms at the time of randomization, a common alternative for adults with Long COVID cognitive symptoms who do not receive Individual Therapy.
Study NCT06789393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients will receive dexmedetomidine (0.5 mcg/kg).
Study NCT06789393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Penile block with bupivacaine 0.25% (0.2 ml/kg)
Study NCT06789393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Penile block with bupivacaine 0.25% (0.2 ml/kg)
Study NCT06789887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy
Description: Written Exposure Therapy (WET) is a 5-session, trauma-focused intervention in which individuals write about their traumatic experience following scripted instructions.
Study NCT06789887 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment as usual (TAU) will be available to all patient participants. Treatment as usual may include various forms of psychotherapy and or medication management.
Study NCT06789887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Description: Treatment as usual (TAU) will be available to all patient participants. Treatment as usual may include various forms of psychotherapy and or medication management.
Study NCT04629729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent
Study NCT06788626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Description: 0.5mg semaglutide injection before and 1 week after endovascular treatment.
Study NCT06788626 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical treatment
Description: Standard medical management
Study NCT06788626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical treatment
Description: Standard medical management
Study NCT06790186 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Perceive, Recall, Plan and Perform intervention Interventions:
Description: The PRPP is a standardized system which determines the impact of information processing on performance of everyday activities. It is a method for assessment of performance mastery, and efficient use of cognitive strategies, as well as a model of intervention to train mastery and cognitive strategy use, in everyday activities. The PRPP assess task performance mastery, as well as cognitive strategy application
Study NCT04604977 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness
Description: Patients are followed with a standardized program including: education and support for behavioral measures, behavioral sessions, by mindfulness, once per week for 45 minutes for 6 weeks which usually delivered in groups of 4 - 8 patients.
Study NCT04629729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Biologic response modifier
Study NCT06146972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod 25mg bid + tofacitinib 5mg bid
Study NCT05967715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: high intensity interval training
Study NCT05967715 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: VSL#3# Probiotic
Study NCT05967715 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Probiotic Placebo
Study NCT04629729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Lympho-conditioning agent
Study NCT06109415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: 400 mg
Study NCT06109415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 100 mg
Study NCT06109415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg
Study NCT06109415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 400 mg
Study NCT06109415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 1 g
Study NCT06109415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1 g
Study NCT06109415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer lock applicator
Description: Applicator for instillation
Study NCT06565221 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat and negative pressure
Description: Heat and negative pressure applied to the feet
Study NCT05398770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D supplementation (30 µg/d)
Description: The participants will be instructed to take the tablets (vitamin D or placebo) once a day 4 weeks prior to the onset of the non-surgical periodontal treatment (NSPT), and to continue for two weeks after their first NSPT, altogether 6 weeks.
Study NCT05398770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (30 µg/d)
Description: The participants will be instructed to take the tablets (vitamin D or placebo) once a day 4 weeks prior to the onset of the non-surgical periodontal treatment (NSPT), and to continue for two weeks after their first NSPT, altogether 6 weeks.
Study NCT06050915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DISC-3405
Description: DISC-3405 is administered as a single dose IV infusion or subcutaneous injection
Study NCT06050915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DISC-3405
Description: DISC-3405 is administered in multiple ascending doses as an IV infusion or subcutaneous injection
Study NCT06050915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered as a single dose IV infusion or subcutaneous injection
Study NCT06050915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered in multiple ascending doses as an IV infusion or subcutaneous injection
Study NCT06527040 — intervention group
Intervention type: OTHER
Intervention: Opioid Transitions Clinical Decision Support (CDS)
Description: Clinical decision support in the form of an electronic health record (EHR) integrated, provider-facing alert suggesting (a) the patient is transitioning to a new phase of opioid therapy and (b) the provider should review patient pain data and pain management goals as suggested by Center for Disease Control and Prevention (CDC) guidelines.
Study NCT06788301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior Alveolar Nerve Block
Description: local anesthesia administration (inferior alveolar nerve block)
Study NCT05560724 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Anodal stimulation or sham
Study NCT05560724 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Anodal stimulation or sham
Study NCT06788301 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Inferior Alveolar Nerve Block
Description: local anesthesia administration (inferior alveolar nerve block)
Study NCT06788301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR eyeglasses
Description: VR eyeglasses was used to distarct patients from dental environment during inferior alveolar nerve block.
Study NCT06788301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy device
Description: Buzzy device was used to distarct patients from dental environment during inferior alveolar nerve block.
Study NCT06789016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the erector spine plane block
Study NCT06789016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9%NaCl
Description: administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the erector spine plane block
Study NCT06789172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day
Study NCT06789172 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV every 3 weeks
Study NCT05660798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: heated tobacco - lifestyle intervention
Description: Patients unable (unwilling) to stop smoking will be randomized to either combustion (C) or heated (H) tobacco groups.
Study NCT03883893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous acetaminophen
Description: Intravenous acetaminophen will be given in the OR.